Advertisement
CLYM vs LXEO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYM is a Buy and LXEO is a StrongBuy.
CLYM in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 26, 2026
CLYM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 38 cases where CLYM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLYM's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 70 cases where CLYM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on CLYM as a result. In 99 of 127 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CLYM just turned positive on October 20, 2026. Looking at past instances where CLYM's MACD turned positive, the stock continued to rise in 46 of 58 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLYM advanced for three days, in 196 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLYM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLYM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.458) is normal, around the industry mean (3.154). P/E Ratio (-12.500) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CLYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LXEO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 25 cases where LXEO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LXEO's RSI Oscillator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LXEO as a result. In 39 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 26 of 31 cases over the following month. The odds of a continued upward trend are 84%.
Following a +15.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LXEO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.097) is normal, around the industry mean (3.154). P/E Ratio (-3.568) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| CLYM | LXEO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 89% |
| Advances ODDS (%) | 3 days ago 81% | 4 days ago 84% |
| Declines ODDS (%) | 6 days ago 89% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLYM’s FA Score shows that 2 FA rating(s) are green while LXEO’s FA Score has 1 green FA rating(s).
- CLYM’s FA Score: 2 green, 3 red.
- LXEO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLYM’s TA Score shows that 6 TA indicator(s) are bullish while LXEO’s TA Score has 5 bullish TA indicator(s).
- CLYM’s TA Score: 6 bullish, 2 bearish.
- LXEO’s TA Score: 5 bullish, 3 bearish.
Price Growth
CLYM (@Biotechnology) experienced а +0.59% price change this week, while LXEO (@Biotechnology) price change was +12.14% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
CLYM is expected to report earnings on Nov 05, 2026.
LXEO is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLYM and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To CLYM | 1D Price Change % | ||
|---|---|---|---|---|
| CLYM | 100% | -0.77% | ||
| KYTX - CLYM | 43% Loosely correlated | -3.08% | ||
| IMNM - CLYM | 42% Loosely correlated | -0.44% | ||
| FDMT - CLYM | 40% Loosely correlated | -6.89% | ||
| LXEO - CLYM | 40% Loosely correlated | +2.61% | ||
| IMVT - CLYM | 38% Loosely correlated | -1.59% | ||
More | ||||
LXEO and
Correlation & Price change
A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with PRME. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To LXEO | 1D Price Change % | ||
|---|---|---|---|---|
| LXEO | 100% | +2.61% | ||
| PRME - LXEO | 52% Loosely correlated | -9.92% | ||
| SLDB - LXEO | 52% Loosely correlated | -2.97% | ||
| KURA - LXEO | 51% Loosely correlated | -2.84% | ||
| EDIT - LXEO | 50% Loosely correlated | -8.87% | ||
| RCKT - LXEO | 50% Loosely correlated | -3.94% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| WNTR | 16.17 | 0.76 | +4.93% |
| YieldMax MSTR Short Option Income Strategy ETF | |||
| DWWN | 23.82 | N/A | N/A |
| Principal Long Duration ETF (DWWN) | |||
| VIGI | 98.17 | -0.33 | -0.34% |
| Vanguard International Dividend Appreciation ETF (VIGI) | |||
| PAXS | 12.93 | -0.10 | -0.77% |
| PIMCO Access Income Fund | |||
| QQQY | 20.45 | -0.75 | -3.54% |
| Defiance Nasdaq 100 Weekly Distribution ETF (QQQY) | |||